8-K: Dare Bioscience Secures $15 Million Stock Purchase Agreement with Lincoln Park Capital

Dare Bioscience has entered into a $15 million stock purchase agreement with Lincoln Park Capital, providing the company with flexible access to capital.

Summary

• Dare Bioscience has entered into a purchase agreement with Lincoln Park Capital for up to $15 million in shares of common stock.
• The agreement allows Dare to sell shares to Lincoln Park at its discretion over a 24-month period.
• Lincoln Park is obligated to purchase shares when directed by Dare, subject to certain conditions and limitations.
• The purchase price per share will be based on the prevailing market price of Dare's common stock at the time of each sale.
• Dare intends to use the proceeds for working capital and general corporate purposes.
• The company issued 137,614 shares to Lincoln Park as consideration for their commitment.
• Dare must file a registration statement with the SEC by December 5, 2024, to enable Lincoln Park to resell the shares.
• The agreement includes a provision that Dare cannot issue more than 19.99% of its outstanding shares without shareholder approval or meeting a minimum average price of $3.59 per share.
• Lincoln Park is restricted from short selling or hedging Dare's stock during the term of the agreement.

Sentiment

Score: 7

Explanation: The document is generally positive as it secures funding for the company, but there are potential risks of dilution and market volatility. The agreement is structured in a way that is beneficial to the company, but the market reaction is uncertain.

Positives

• The agreement provides Dare with access to up to $15 million in capital.
• Dare has control over the timing and amount of share sales.
• The agreement does not include warrants, rights of first refusal, participation rights, penalties, or liquidated damages.
• Lincoln Park is obligated to purchase shares when directed by Dare, providing a reliable source of funding.
• The proceeds can be used for working capital and general corporate purposes, offering flexibility.
• Lincoln Park is restricted from short selling or hedging Dare's stock, which may help stabilize the share price.

Negatives

• The agreement could lead to dilution of existing shareholders if a large number of shares are sold.
• The price per share is based on prevailing market prices, which could be lower than desired by the company.
• The company is limited to selling 19.99% of its outstanding shares without shareholder approval or meeting a minimum average price of $3.59 per share.
• The company is obligated to file a registration statement with the SEC by December 5, 2024, which could be a burden.

Risks

• The company's ability to access capital under the agreement depends on market conditions and the trading price of its stock.
• The net proceeds received will depend on the frequency and prices at which shares are sold to Lincoln Park.
• There is a risk of dilution for existing shareholders if a significant number of shares are issued.
• The company's stock price could be negatively impacted if the market perceives the agreement as a sign of financial weakness.
• The company's ability to use the proceeds effectively for working capital and general corporate purposes is not guaranteed.

Future Outlook

The company expects that any proceeds received from the sale of shares will be used for working capital and general corporate purposes, including advancing their portfolio of novel investigational products in women's health.

Management Comments

• Sabrina Martucci Johnson, President and CEO, stated that the transaction may provide Dare with access to capital to help advance their portfolio of novel investigational products in women's health.
• She highlighted Sildenafil Cream, 3.6%, as a key product in development, with an estimated Phase 3 study cost of approximately $15 million.

Industry Context

This agreement is a common method for biotech companies to raise capital, especially those in the development stage. It allows for flexible funding without the immediate need for a large, dilutive offering. The focus on women's health aligns with a growing trend in the pharmaceutical industry to address unmet needs in this area.

Comparison to Industry Standards

• The use of a stock purchase agreement with an institutional investor like Lincoln Park Capital is a fairly standard practice for biotech companies seeking flexible funding.
• The 19.99% share issuance cap is a common feature to avoid the need for shareholder approval under Nasdaq rules.
• The 24-month period for the agreement is typical for such arrangements, allowing the company to access capital over time as needed.
• The lack of warrants, rights of first refusal, participation rights, penalties, or liquidated damages is favorable for Dare, providing more flexibility and control.
• The agreement's structure is similar to other at-the-market (ATM) offerings, but with a specific investor commitment.

Stakeholder Impact

• Shareholders may experience dilution if a significant number of shares are issued.
• Employees may benefit from the company's increased financial stability and ability to fund operations.
• Customers may benefit from the company's ability to advance its product pipeline.
• Creditors may view the agreement positively as it improves the company's financial position.

Next Steps

• Dare will file a registration statement with the SEC by December 5, 2024.
• Dare will begin selling shares to Lincoln Park at its discretion after the registration statement is declared effective.
• Dare will use the proceeds for working capital and general corporate purposes, including advancing its product pipeline.

Key Dates

Keywords

stock purchase agreement, capital raise, Lincoln Park Capital, share issuance, working capital, common stock, registration rights, biopharmaceutical, womens health, funding